| Literature DB >> 30470234 |
Else Quist-Paulsen1,2, Pål Aukrust3,4,5,6,7, Anne-Marte Bakken Kran8,5,9, Oona Dunlop10, Vidar Ormaasen11, Birgitte Stiksrud11,8, Øivind Midttun12, Thor Ueland3,5,6,7, Per Magne Ueland12, Tom Eirik Mollnes8,6,7,13,14,15,16, Anne Ma Dyrhol-Riise11,8,6,17.
Abstract
BACKGROUND: The host response to intruders in the central nervous system (CNS) may be beneficial but could also be harmful and responsible for neurologic symptoms and sequelae in CNS infections. This immune response induces the activation of the kynurenine pathway (KP) with the production of neuroactive metabolites. Herein, we explored cytokine and KP responses in cerebrospinal fluid (CSF) and serum in patients with encephalitis, aseptic, and bacterial meningitis.Entities:
Keywords: Aseptic meningitis; Bacterial meningitis; Chemokines; Cytokines; Encephalitis; Indoleamine 2,3-dioxygenase; Kynurenine tryptophan pathway; Neopterin
Mesh:
Substances:
Year: 2018 PMID: 30470234 PMCID: PMC6260858 DOI: 10.1186/s12974-018-1366-3
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Fig. 1Schematic presentation of the KP pathway. IDO is the main enzyme responsible for the TRP catabolism in CNS. KYN is further degraded into the neuroprotective NMDAr antagonist KYNA by KAT, or by KMO and KYNU into the neurotoxic metabolites of 3-HK and QA. QA is an agonist of the NMDA receptor. Abbreviations: AA, anthranilic acid; 3-HAA, 3-hydroxyanthranilic acid; HAO, 3-hydroxyanthranilic acid oxidase; 3-HK, 3-hydroxykynurenine; IDO, indoleamine-2,3-dioxygenase; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; KYN, kynurenine; KYNA, kynurenic acid; KYNU, kynureninase; QA, quinolinic acid; PIC, picolinic acid; TRP, tryptophan; XA, xanthurenic acid. Bold box indicates neuroprotective metabolite, dashed boxes indicate neurotoxic metabolites in the KP pathway
Patient characteristics and clinical presentation
| Parameter | Encephalitis ( | ASM ( | ABM ( | Controls ( | |
|---|---|---|---|---|---|
| Gender, males (%) | 4 (40) | 10 (40) | 4 (67) | 13 (31) | 0.385 |
| Age, years | 43.5 (30, 72) | 35 (28, 48) | 52 (41, 68) | 31 (22, 41) | 0.054 |
| Hospital stay, days | 19 (11, 42)b | 3 (1.5, 5.5)c | 19 (14, 33)b, d | 2.0 (1.0, 4.0) |
|
| Comorbidity (%) | |||||
| Immunodeficiencye | 2 (30)b | 1 (4)c | 1 (17)b | – |
|
| Psychiatric disorder | 2 (20)b | 2 (8) | – | – |
|
| Etiology known (%)f | 4/10 (40) | 16/25 (64) | 6/6 (100) | – |
|
| Headache (%) | 7/10 (70)b | 24/25 (96)c | 3/4 (75) | 39/41 (95) |
|
| Neck stiffness (%)g | 2/10 (20) | 12/25 (48) | 3/5 (60) | 12/42 (29) | 0.175 |
| Objective fever (%)h | 7/10 (70) | 17/25 (68) | 5/6 (83) | 20/42 (48) | 0.168 |
| Focal neurology (%) | 5/9 (56)b | 2/19 (10)c | 1/6 (17) | 1/24 (4) |
|
| GCS ≤ 14 (%) | 10/10 (100)b | 2/25 (8)c | 5/6 (83)b,d | 6/42 (14) |
|
| CSF WBC (× 106/L) | 25 (9.5, 92)b | 179 (26, 271)b, c | 212 (91, 1434)b, c | 1.0 (1.0, 2.0) |
|
| CSF protein (g/L) | 0.57 (0.4, 0.9)b | 0.59 (0.4, 0.8)b | 2.2 (0.8, 5.9)b, c, d | 0.26 (0.2, 0.3) |
|
| CSF glucose (mmol/L) | 3.6 (3.3, 4.4) | 3.5 (3.0, 3.7) | 3.6 (0.4, 6.3) | 3.5 (3.2, 3.7) | 0.341 |
| Glucose ratio | 0.6 (0.5, 0.7) | 0.6 (0.5, 0.6)b | 0.4 (0.1, 0.6)b | 0.6 (0.6, 0.7) |
|
| Albumin ratio | 8.4 (6.5,14)b | 9.4 (6.1, 13)b | 79 (36, 137)b, c, d | 4.0 (2.6, 5.0) |
|
| Blood WBC (× 109/L) | 8.6 (7.4, 11) | 8.2 (6.1, 11) | 14 (8.5, 18) | 10 (6.7, 12) | 0.173 |
| CRP, serum (mg/L) | 6 (0.9, 86) | 3.5 (1.3, 12)b | 169 (96, 446)b, c, d | 16 (2.1, 77) |
|
CSF WBC white blood cell count in CSF, glucose ratio CSF glucose/serum glucose, albumin ratio CSF albumin/serum albumin. Significant p-values are marked in bold.
Data shown are median (IQR) or numbers/n (%)
ap values for one way analysis of variance (Kruskal-Wallis)
bp < 0.05 for analysis with Mann-Whitney U test (MWU) in comparison with the control group
cp < 0.05 for analysis with MWU in comparison with encephalitis
dp < 0.05 for analysis with MWU in comparison with ASM
eUnder treatment for or treated for cancer within the last year (including hematological malignancies), HIV infection or diabetes mellitus type 2 (DM2), or using immunosuppressive or immune modulating drugs
fCausing agents for encephalitis were 3 viral (adenovirus, HSV1, VZV) and 1 NMDAr encephalitis. ABM; Streptococcus pneumonia (n = 2), Staphylococcus aureus (n = 2), Neisseria meningitides (n = 1), and Haemophilus influenzae (n = 1). ASM; HSV2 (n = 6), enterovirus (n = 8), Toscana virus (n = 1), and 1 patient had intrathecal antibody production of IgG against Borrelia burgdorferi
gNeck stiffness was assessed by a physician before LP
hFever was defined as either ≥ 38 °C upon admission or within 24 h after admission, or measured to ≥ 38 °C by the patient prior to admission
Fig. 2Cytokines in CSF in patients with encephalitis (Enc, n = 10), aseptic meningitis (ASM, n = 25), bacterial meningitis (ABM, n = 6) in comparison with controls (Ctr, n = 42). Data shown are medians with IQR and all were significant by the Kruskal-Wallis test. Comparisons of two groups were analyzed by using Mann-Whitney U test. Asterisks above patient groups indicate significant difference vs controls, asterisks above horizontal lines indicate significant differences between individual groups (Mann-Whitney U test): *p < 0.05, **p < 0.01, and ***p < 0.001. Values below the detection limit were set to the lowest detectable level for that analyte
Fig. 3Cytokines in serum in patients with encephalitis (Enc, n = 10), aseptic meningitis (ASM, n = 20), bacterial meningitis (ABM, n = 6) in comparison with controls (Ctr, n = 41). Data shown are medians with IQR. Asterisks above patient groups indicate significant difference vs controls, asterisks above horizontal lines indicate significant differences between individual groups (Mann-Whitney U test): *p < 0.05, **p < 0.01, and ***p < 0.001. Values below the detection limit were set to the lowest detectable level for that analyte
Fig. 4Neopterin, kynurenine metabolites, and ratios in patients with encephalitis (Enc, n = 10), viral meningitis (VM, n = 12), and bacterial meningitis (ABM, n = 6) in comparison with controls (Ctr, n = 22). Data shown are median with IQR, and all were significant in the analysis of variance with the Kruskal-Wallis test. Comparisons of two groups were analyzed by Mann-Whitney U test. Asterisks above patient groups indicate significant difference vs controls, asterisks above horizontal lines indicate significant differences between individual groups (Mann-Whitney U test): *p < 0.05, **p < 0.01, and ***p < 0.001. a: TRP levels below the lower level of detection (LOD) for 9 patients with CNS infection were adjusted to this value (0.4 μM) for calculation of the KYN/TRP ratio as the expression of IDO activity (KYN (nmol)/TRP(μmol))
Fig. 5Correlations of neopterin and IP-10, as markers of IFN-ƴ activity, with activation of the KP. a Neopterin vs KYN/ TRP ratio (IDO) (n = 50; Rho 0.9, p < 0.001). b IP-10 vs KYN/TRP ratio (IDO) (n = 50; Rho 0.8, p < 0.001). c Neopterin vs KYNA/(3-HK + QA) ratio (n = 50; Rho − 0.7, p < 0.001). d IP-10 vs KYNA/(3-HK + QA) ratio (n = 50, Rho − 0.5, p < 0.001). Data shown are obtained by Spearman’s rank correlation